Condensed azines as inhibitors of cyclic ADP-ribose hydrolase

Compounds inhibiting CD38 enzyme activity address NAD+ dysregulation in medical conditions, effectively treating neurodegenerative diseases by restoring NAD+ levels.

JP2026521417APending Publication Date: 2026-06-30FLAGSHIP PIONEERING INNOVATIONS VI LLC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
FLAGSHIP PIONEERING INNOVATIONS VI LLC
Filing Date
2024-06-07
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

Dysregulation of NAD+ levels is associated with various medical conditions, including obesity, diabetes, cancer, heart disease, asthma, and inflammation, and increasing CD38 expression leads to NAD+ depletion, necessitating a need for small molecule inhibitors to modulate CD38 activity for therapeutic benefits.

Method used

Development of compounds that inhibit CD38 enzyme activity, represented by specific chemical structures, to restore normal NAD+ levels and treat diseases associated with CD38 expression and decreased cellular NAD+ levels.

Benefits of technology

The compounds effectively inhibit CD38 activity, potentially treating neurodegenerative diseases like Parkinson's, Alzheimer's, and Huntington's by increasing NAD+ levels, offering therapeutic benefits for these conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026521417000001_ABST
    Figure 2026521417000001_ABST
Patent Text Reader

Abstract

This disclosure provides compounds, in part, compounds of formula (I) or formula (II), and their use in the treatment of medical diseases or disorders such as neurodegenerative diseases (e.g., Parkinson's disease). Methods for preparing the pharmaceutical compositions and compounds of this disclosure are provided. The compounds are intended to be modulators, e.g., inhibitors, of cyclic ADP-ribose hydrolase (CD38). This disclosure covers compounds that modulate, e.g., inhibit the expression and / or activity of CD38, at least in part. Pharmaceutical compositions comprising at least one disclosed compound and pharmaceutically acceptable excipients are also disclosed herein. TIFF2026521417000143.tif28170
Need to check novelty before this filing date? Find Prior Art